Logo

    Reviewing the Role of JAK Inhibitors in Atopic Dermatitis

    enMarch 16, 2022
    What was the main topic of the podcast episode?
    Summarise the key points discussed in the episode?
    Were there any notable quotes or insights from the speakers?
    Which popular books were mentioned in this episode?
    Were there any points particularly controversial or thought-provoking discussed in the episode?
    Were any current events or trending topics addressed in the episode?

    About this Episode

    Host: Matthew S. Keller MD
    Guest: Shawn Kwatra, MD

    As the most common type of eczema, atopic dermatitis is a chronic, inflammatory skin disorder that affects millions of people worldwide. And although it’s a complex disease with no cure, the FDA recently approved two oral JAK-1 inhibitors for patients with mild-to-severe-symptoms. So what do we need to know about these new treatment options? Joining Dr. Matthew Keller to review the role of JAK inhibitors in atopic dermatitis is Dr. Shawn Kwatra, Associate Professor of Dermatology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Itch Center.

    Recent Episodes from Dermatology

    Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

    Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
    Guest: Terry Faleye, MPAS, PA-C
    Guest: Jonathan I. Silverberg, MD, PhD, MPH

    Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.

    Understanding the Impact of Depressive Symptoms in Patients with Psoriasis

    Understanding the Impact of Depressive Symptoms in Patients with Psoriasis
    Host: Charles Turck, PharmD, BCPS, BCCCP
    Guest: Neda Shahriari, MD

    This study assessed the link between depressive symptoms in real-world patients with psoriasis to help identify characteristics for those at risk. What were the findings? To learn more, join Dr. Charles Turck as he speaks with Dr. Neda Shahriari, Board-Certified Dermatologist at Brigham and Women’s Hospital in Boston, Massachusetts.

    Strategies for the Long-Term Control of Atopic Dermatitis

    Strategies for the Long-Term Control of Atopic Dermatitis
    Host: Raj Chovatiya, MD, PhD
    Guest: Melinda Gooderham, MSc, MD, FRCPC

    Due to the evolving treatment landscape, the way we think about treating adult and elderly patients with atopic dermatitis has shifted. So what are some special considerations we need to think about when selecting a treatment option for long-term control, and how can we best involve patients in the decision-making process? Joining Dr. Raj Chovatiya to help answer these and other key questions in atopic dermatitis care is Dr. Melinda Gooderham, Medical Director for the SKiN Center for Dermatology in Peterborough, Ontario.

    Poster Pearl: Itch Control Matters Most to Patients with Moderate-to-Severe Atopic Dermatitis

    Poster Pearl: Itch Control Matters Most to Patients with Moderate-to-Severe Atopic Dermatitis
    Host: Raj Chovatiya, MD, PhD
    Guest: Steven R. Feldman, MD, PhD

    To gain a better understanding of the different treatment attributes that patients with moderate-to-severe atopic dermatitis value most, a discrete choice experiment was conducted. And now, the results are in, with itch control being the top attribute. Joining Dr. Raj Chovatiya to share this and other key findings from his research that was featured as a poster at the 2023 Fall Clinical Dermatology conference is Dr. Steven Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

    Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation

    Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
    Guest: Cara Dolin, MD
    Guest: Jennifer Simpson
    Guest: Diana Girnita, MD ,PhD

    Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.

    Diving into the Details of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis

    Diving into the Details of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis
    Host: Charles Turck, PharmD, BCPS, BCCCP
    Guest: Ananta Paine, PhD

    The diagnosis of psoriatic arthritis has not been easy due to the lack of knowledge about an established biomarker. To learn more, join Dr. Charles Turck as he speaks with Dr. Ananta Piane, Principal Investigator and Research Assistant Professor at the University of Rochester Medical Center in Rochester, New York, to discuss his 500-patient cohort study to find out if there are underlying differences of psoriasis patients who did not convert to psoriatic arthritis with those who did.

    Biosimilars in Psoriasis: The Future of Treatment

    Biosimilars in Psoriasis: The Future of Treatment
    Host: Raj Chovatiya, MD, PhD
    Guest: Steven R. Feldman, MD, PhD

    The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

    Psoriasis Treatment Redefined: Exploring the Impact of IL-23 Inhibitors

    Psoriasis Treatment Redefined: Exploring the Impact of IL-23 Inhibitors
    Host: Raj Chovatiya, MD, PhD
    Guest: George Han, MD, PhD

    The discovery of the IL-23 pathway has revolutionized the treatment of psoriasis. Learn more about the current state of IL-23 inhibition in psoriasis management with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

    Applying Shared Decision-Making to Atopic Dermatitis Care

    Applying Shared Decision-Making to Atopic Dermatitis Care
    Host: Raj Chovatiya, MD, PhD
    Guest: Matthew Zirwas, MD
    Guest: Douglas DiRuggiero, DMSc, PA-C

    When managing atopic dermatitis, it’s up to the patient to determine how much therapeutic intervention they want to pursue, which underscores the importance of applying shared decision-making to practice. Joining Dr. Raj Chovatiya to share their perspectives on how we can utilize shared decision-making in atopic dermatitis care are Dr. Matthew Zirwas and Mr. Douglas DiRuggiero. Dr. Zirwas founded Bexley Dermatology Research Clinic in Columbus, Ohio where he specializes in adult eczema, and Mr. DiRuggiero is a certified physician assistant at the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.

    Treating Atopic Dermatitis: A Look at the Current & Future Landscape

    Treating Atopic Dermatitis: A Look at the Current & Future Landscape
    Host: Raj Chovatiya, MD, PhD
    Guest: Jennifer Soung, MD
    Guest: Einjuan James Song, MD, FAAD

    The atopic dermatitis treatment landscape has evolved over the past several years. To catch up on the current treatment options available and the novel therapies in development, Dr. Raj Chovatiya speaks with Drs. James Song and Jennifer Soung. Dr. Song is the Director of Clinical Research for Frontier Dermatology Partners in Everett, Washington, and Dr. Soung is the Director of Clinical Research at Southern California Dermatology in Santa Ana, California.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io